Aditxt, Inc. and SphereDX Launch AditxtScore™ for COVID-19 in Kentucky, Ohio and Indiana to Address Individual Immune Status Uncertainty and Help Evaluate Cadence for Booster Shots
Aditxt (NASDAQ: ADTX) has partnered with SphereDX to offer the AditxtScore for COVID-19, a comprehensive immune response monitoring tool. Initial tests in assisted living facilities revealed that one-third of vaccinated residents had suboptimal immune responses, with 8.1% showing no immune response. This partnership aims to enhance immune monitoring across Kentucky, Ohio, and Indiana, helping individuals make informed decisions regarding booster vaccinations and preventive measures. AditxtScore offers a detailed analysis of immune responses to various COVID-19 antigens.
- Partnership with SphereDX to provide AditxtScore for COVID-19 expands market reach.
- Pilot program indicated that AditxtScore can identify individuals needing booster shots, enhancing public health response.
- Potential for increased demand as AditxtScore offers detailed immune response data.
- One-third of tested vaccinated residents showed suboptimal immune responses, raising concerns about vaccine effectiveness.
- 8.1% of residents had no discernible immune response, indicating potential gaps in immunity among the vaccinated population.
Initial AditxtScore testing found one-third of fully vaccinated assisted living community residents needed booster vaccinations to strengthen individual antibody response
Under the agreement, SphereDX will make the AditxtScore for COVID-19 available throughout its laboratory locations serving
“There is so much uncertainty out there right now with
SphereDX conducted a pilot program deploying the AditxtScore for COVID-19 in a group of area assisted living facilities. Testing a total of 99 fully vaccinated residents ages 63 to 99, the results showed that
“If we really want to get ‘back to normal’ with confidence, we are going to need personalized immune testing that delivers detailed information on the strength and durability of each individual’s immune response,” said
AditxtScore for COVID-19, which was first introduced in
The level of precision in AditxtScore for COVID-19, along with its ability to measure the neutralizing activity of IgG, IgM and IgA isotopes, can provide clinicians with the data they need to understand the strength and quality of each individual’s immune response to COVID-19. This information can be used to guide further intervention for those who have not developed a strong immune response and to reassure those who have developed a strong response that no further action is required.
This information is particularly important for the millions of immunocompromised patients who may not develop an adequate immune response to vaccination or exposure for multiple reasons, including: immunosuppressive disease, immunosuppressant medications, anti-cancer medications affecting immune function, or the presence of long-term chronic disease that has exhausted the body’s natural immune response capacity.
AditxtScore for COVID-19 is offered through authorized channel partners. To find an AditxtScore Channel Partner near you, please visit www.aditxtscore.com. AditxtScore for COVID-19 is available for use as a CLIA-validated laboratory developed test (LDT). This test is not for self-diagnosis and is not cleared or approved by the FDA.
About
Forward-Looking Statements
Certain statements in this press release constitute “forward-looking statements” within the meaning of federal securities laws. Forward-looking statements include statements regarding the Company’s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the Company’s ongoing and planned product and business development; the Company’s intellectual property position; the Company’s ability to develop commercial functions; expectations regarding product launch and revenue; the Company’s results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as those risks more fully discussed in the section titled “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s other filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20210909005562/en/
Media and Investor Relations Contact:
Chief Communications Officer
ir@aditxt.com
Source:
FAQ
What is the AditxtScore for COVID-19?
What were the findings from the assisted living facility pilot program?
Which states will AditxtScore for COVID-19 be available in?
When was AditxtScore for COVID-19 introduced?